These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair. Fan Z; Luo H; Zhou J; Wang F; Zhang W; Wang J; Li S; Lai Q; Xu Y; Wang G; Liang A; Xu J Oncol Rep; 2020 Nov; 44(5):2152-2164. PubMed ID: 32901871 [TBL] [Abstract][Full Text] [Related]
44. Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing Duabil AJ; Cooper CR; Aldujaily E; Halford SE; Hirschberg S; Katugampola SD; Jones GD Explor Target Antitumor Ther; 2023; 4(5):1210-1226. PubMed ID: 38214010 [TBL] [Abstract][Full Text] [Related]
45. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells. Thompson R; Meuth M; Woll P; Zhu Y; Danson S Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433 [TBL] [Abstract][Full Text] [Related]
46. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614 [TBL] [Abstract][Full Text] [Related]
47. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. Bryant C; Rawlinson R; Massey AJ BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095 [TBL] [Abstract][Full Text] [Related]
48. TLC388 Induces DNA Damage and G2 Phase Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cells. Wu KM; Chi CW; Lai JC; Chen YJ; Kou YR Cancer Control; 2020; 27(1):1073274819897975. PubMed ID: 32281394 [TBL] [Abstract][Full Text] [Related]
49. Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε. Sviderskiy VO; Blumenberg L; Gorodetsky E; Karakousi TR; Hirsh N; Alvarez SW; Terzi EM; Kaparos E; Whiten GC; Ssebyala S; Tonzi P; Mir H; Neel BG; Huang TT; Adams S; Ruggles KV; Possemato R Mol Cell; 2020 Nov; 80(4):682-698.e7. PubMed ID: 33152268 [TBL] [Abstract][Full Text] [Related]
50. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. Wayne J; Brooks T; Massey AJ Oncotarget; 2016 Dec; 7(51):85033-85048. PubMed ID: 27829224 [TBL] [Abstract][Full Text] [Related]
52. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells. Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335 [TBL] [Abstract][Full Text] [Related]
54. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205 [TBL] [Abstract][Full Text] [Related]
55. Interferon-gamma enhances radiation-induced cell death via downregulation of Chk1. Kim KS; Choi KJ; Bae S Cancer Biol Ther; 2012 Sep; 13(11):1018-25. PubMed ID: 22825336 [TBL] [Abstract][Full Text] [Related]
56. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211 [TBL] [Abstract][Full Text] [Related]
57. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. Liang M; Zhao T; Ma L; Guo Y Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153 [TBL] [Abstract][Full Text] [Related]
58. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Martino-Echarri E; Henderson BR; Brocardo MG Oncotarget; 2014 Oct; 5(20):9889-900. PubMed ID: 25301724 [TBL] [Abstract][Full Text] [Related]
59. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188 [TBL] [Abstract][Full Text] [Related]
60. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Santoro A; Pisanti S; Grimaldi C; Izzo AA; Borrelli F; Proto MC; Malfitano AM; Gazzerro P; Laezza C; Bifulco M Int J Cancer; 2009 Sep; 125(5):996-1003. PubMed ID: 19479993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]